- Previous Close
0.0170 - Open
0.0150 - Bid 0.0142 x --
- Ask 0.0181 x --
- Day's Range
0.0150 - 0.0150 - 52 Week Range
0.0040 - 0.0750 - Volume
10,000 - Avg. Volume
162,437 - Market Cap (intraday)
6.774M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. Therma Bright Inc. serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
www.thermabright.comRecent News: TBRIF
View MorePerformance Overview: TBRIF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TBRIF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TBRIF
View MoreValuation Measures
Market Cap
6.35M
Enterprise Value
6.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
316.26
Price/Book (mrq)
6.33
Enterprise Value/Revenue
364.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.82%
Return on Equity (ttm)
-202.66%
Revenue (ttm)
28.81k
Net Income Avi to Common (ttm)
-3.11M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
35.62k
Total Debt/Equity (mrq)
4.09%
Levered Free Cash Flow (ttm)
-1.17M